|
|
 |
April 1, 2008 |
Now Available:
Download the podcast of Dr. Strober's presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment. MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Dr. Bruce Strober presents "Management Strategies for Psoriasis: Benefit, Safety, and Risk with Biologics" from our new 5-part series, "Practical Approaches to Solving Psoriasis Challenges"
Arthritis: CRP, Anti-CCP, Ultrasound Can Predict Which RA Patients Need Early, Aggressive Treatment to Stave Off Rapid Progression
RA patients with rapidly progressing disease will benefit most from aggressive early treatment with biologics and can be identified using markers such as CRP, anti-CCP, and ultrasound evidence of joint erosion...
New from PubMed: Analysis of Contrast-Enhanced MRI of Hands and Wrists in Patients with Psoriatic Arthritis
Contrast-enhanced MRI demonstrates bone marrow edema, erosions, tendon and soft tissue disease, and median nerve involvement in patients with PsA of the hands and wrists...
BioPharm Business: Targeted Genetics Announces Completion of Dosing for Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis
Dosing has been completed for Targeted Genetic's phase I/II clinical trial of tgAAC94 administered directly to affected joints of subjects with inflammatory arthritis to reduce inflammation and to avoid the potential for systemic side effects...
BioPharm Business: Trubion Announces SBI-087, a Fully Humanized CD20-directed Compound, as Next-Generation Product Candidate for RA and SLE; TRU-015 to Enter Phase IIb RA Clinical Trial
Trubion Pharmaceuticals, Inc announced that its collaboration partner Wyeth Pharmaceuticals has filed an investigational new drug (IND) application for SBI-087 for rheumatoid arthritis (RA), and clinical trial sites are preparing to enroll patients in a phase I study...